ChinaBio® Partnering Forum 2013 Press Releases
April 1, 2013Pharma and biotech executives lead program at ChinaBio® Partnering Forum 2013 in Beijing The fifth annual ChinaBio® Partnering Forum will bring executives from pharmaceutical companies including Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Merck, Novo Nordisk and Sanofi; and leading venture capital firms such as TusPark Ventures, Qiming Venture Partners, Lilly Asia Ventures, OrbiMed Asia and others to Beijing this May 29–30. The 2013 keynote, "P...more ►
February 26, 2013Beijing will host ChinaBio® Partnering Forum 2013Life science partnering event brings Western biopharma dealmakers to China
EBD Group, the premier partnering conference firm for the life science industry, and ChinaBio® LLC, a leading consulting firm in Shanghai, announced that the fifth annual ChinaBio® Partnering Forum 2013 will be held May 29–30 at the Shangri-La Hotel Beijing. The 2012 forum was attended by 719 delegates from 402 companies and 23 countries who engaged in more th...more ►
Latest headlines from partneringNEWS™
3 May 2013 China’s rapid growth nourishes biotech environment “Chinese investors haven’t lost a lot of money in biotech, so they’re in a good mood.” In the West, venture capital is drying up for life science firms so some small companies have come to Asia to raise financing where there is an available supply of money. more ►
3 May 2013 WuXi AppTec: “Every client is a partner” "Our vision is to create platforms so that anyone who wants to explore an idea can come and use the platform in their most effective way to push their idea and innovation. We are always being asked, 'Why don’t you become a pharma company?' But that’s not who we are. For us, it’s about being able to enable innovation across the board. We think it’s a very important mission." more ►
18 March 2013 Human data and teaching buyers won big deals in 2012 A mix of novel science and bold selling strategies won the big bio-bucks and stole headlines as top deals over the past year. A few of the winners shared their secrets in this panel session at BIO-Europe Spring® 2013. more ►
18 March 2013 A view from the West: Trends in biotech venture exits The last year in biotech saw a breakout from prior performance on multiple fronts across stocks, drug approvals, venture returns, and pharma investing. more ►
18 March 2013 Stem cells: Do we need to wait 25 years for the Next Big Thing? With a Nobel Prize in 2012 and phenomenal potential for diagnostics and therapies, no one doubts that the next big thing will be stem cell derived products. In these (very) early days, this BIO-Europe Spring® session presented current initiatives and challenges. more ►
